FDA Cracks Oral Semaglutide Scam; Stocks Barely React
FDA is stepping up within a matter of a few hours on the newest $HIMS oral semaglutide scam. This is a COMPLETE reversal of how the FDA has previously been (insanely) lenient with the mass compounding “personalization” scam that $HIMS has run for the injectable drug. Yet, $NVO is barely up after hours and $HIMS is barely down after hours. I have positioned my portfolio accordingly 🤷🏻♂️
Solid Foundations Beat AI Hype in Bioinformatics
1/ AI won’t save sloppy science. Before you dive into deep learning, master your foundations. Here’s why basic bioinformatics still rules 🧵 https://t.co/nPbaEK3hGf
ApexOnco IPO Highlights Valuation Benchmarks for Biotech
$EIKN prices at $18/share, to raise $381m at a $972m market cap. Here's @ApexOnco on what this IPO tells us: https://t.co/OYpmTI21qI
MAPK‑RUNX1 Axis Controls SMARCA
Spatiotemporal control of SMARCA5 by a MAPK–RUNX1 axis distinguishes mutant KRAS-driven pancreatic malignancy from tissue regeneration https://t.co/eshLHVpD8I https://t.co/mZj4F2qeGp
Curiosity and Mistakes, Not Brilliance, Build Expertise
After 13 years of analyzing sequencing data, I am an "expert" in doing it. I gained those experiences not because I am smarter, but simply because I am curious I made more mistakes, and encountered more problems.
Novo Drops, Eli Lilly Rebounds—GLP‑1 Earnings Cycle Repeats
GLP-1 earnings reports playbook: 1) $NVO: Guys, it’s not looking great for GLP-1 sellers ***$NVO and $LLY sell off*** 2) $LLY: Huh? Nah we’re good. ***$NVO stays down $LLY rips*** 3) Repeat
Novartis Halts PIT565 T‑cell Engager Development
Confirmned discontinuation of $NVS PIT565, which seems to be a specifically targeted T-cell engager (also hit CD2). cf $AZN Titan platform.
DSNKY's DS-3790 DXd ADC Begins Clinical Trials
$DSNKY's first DXd ADC for haematology, DS-3790, enters the clinic. As I reported last November: https://t.co/9CcbISqbqK
New Antibody‑Drug Conjugates Unveiled in Latest Scoop
Several scoops among the latest ADC names. Via @ApexOnco with H/T to @raffcolo -> https://t.co/JxDmId0Q0A
MRK's Interpath-001 Study Fully Enrolled
$MRK confirming that Interpath-001 study of $MRNA partnered intismeran autogene is "ongoing & fully enrolled". No further guidance as to timing of results, due some time in 2026. My earlier take on what to expect: https://t.co/9Pk3JK8TLs
Editor Shares Insights at Nanotech Conference Plenary
Wrapping up two days at the 10th biennial International Conference on Nanoscience and Nanotechnology here in Sydney, Australia. Highly engaging event, where my participation involved serving on a panel discussion with other journal editors and delivering a plenary presentation on our...
FDA Leadership Seeks to Calm Staff over Fast‑track Voucher
#FDA leadership tried today to assuage the concerns of staff over a controversial fast-track program for approving drugs, the Commissioner’s National Priority Voucher, @LizzyLaw_ reports. https://t.co/wsvL9gTBhr
BCMA CAR‑T Shows Near‑Perfect Response in AL Amyloidosis
BCMA CAR-T in AL amyloidosis is starting to look like a real category, not a case report. The Alpha: • Efficacy: 100% hematologic response rate, 78% CR • Durability: 100% PFS and OS at 12 months in a heavily pretreated cohort (median...
CRISPR/dCas9 Epigenome Editors Show Complex On‑off Target Relationship
Comprehensive profiling of CRISPR/dCas9 epigenome editors indicates a complex link between on and off target effects https://t.co/sEH5GH08Hh
Suspect Mycoplasma Contamination When Human Mapping Fails
Your cell line sequencing data isn’t mapping well? Before blaming the aligner—check if you're sequencing bacteria instead of human. Let’s talk about mycoplasma contamination. https://t.co/y8Ydk0i248
NTLA Plunges 25% Despite Hold‑lift Skepticism
$NTLA down >25% since the cultists tried to dunk on me after the hold lift. Down >15% since the high $15s when I made the post below *before* the hold lift, saying that a potential hold lift wouldn't actually...
PolyAseqTrap Enables Universal Genome-Wide polyA Site Mapping
PolyAseqTrap: a universal tool for genome-wide identification and quantification of polyadenylation sites from different 3′ end sequencing data https://t.co/pwEf2GeYjb github https://t.co/gpfYhyMoX3 https://t.co/oyA5MBFutE
Master NGS Pre‑Processing: Raw Data Understanding Is Crucial
1/ Many bioinformatics students don’t know much about NGS pre-processing. But trust me, understanding the raw data is essential. Here’s why. https://t.co/WjT1I9haD8
Dutch Dairy Farm Reports Multiple H5N1‑positive Cows
5 more dairy cows tested positive for #H5N1 #birdflu antibodies on the Dutch farm where a previous cow tested positive. No surprise that if 1 was positive, others would be too. This dairy farm is the first outside the US...
Blood Biomarkers Reveal Cardiometabolic Risk Beyond Weight
New Cardiometabolic clock identified blood biomarkers that associate with disease and early death. While body weight seemingly wasn't a major determinant, these were: HbA1c, creatinine, lymphocyte %, urea nitrogen, RDW, pulse & systolic blood pressure
Turn RNA‑seq Dimensionality Chaos Into Clarity
1/Ever feel buried under 20,000 genes and no clue where to start? That’s the curse of dimensionality in RNA‑seq. Let’s turn chaos into clarity. https://t.co/0U3wdzUsMm
Bioinformatics Analysis Time Varies; Depends on Many Factors
“How long will the bioinformatics analysis take?” If you’ve ever been asked that… you know the answer: It depends. Here’s why: 🧵 https://t.co/PG7Xaj3oxf
CHIP in Blood Sequencing Skews Mutation Detection
1/12 What is “CHIP” in blood sequencing, and why does it mess up mutation calls? Not every mutation is created equal. Quick explainer for oncologists, cardiologists, and genomics folks 👇 https://t.co/nBEWTsdlz3
Academic Software's Hidden Risk: Single‑grad Maintainer Dependency
Academic software is a quiet risk in many analysis pipelines. A lot of core tools are maintained by one grad student whose incentives don't include long-term upkeep. https://t.co/ec4R4kDi84
FDA Greenlights Human Trials for Epigenetic Age Reversal
Story in @fortunemag today about FDA's approval to test epigenetic age reversal in humans www.tinyurl.com/mvyzds8z
Model‑Robotics Loop Accelerates Experimental Discovery Rates
Agree completely with @kevinweil this loop between models and robotic labs works today and it’s going to be exciting the directions that scientists take autonomous labs. Feels inevitable that it will yield a great speed up in our...
Nipah Risk Moderate Locally, Low Globally, Not Like Covid
For those worried about #Nipah virus: Yes, it's a dangerous disease. Yes, India has recently reported 2 cases. But Nipah doesn't spread as easily as Covid. "WHO assesses the risk posed by Nipah to be moderate at the sub-national level, and...
Regeneron Unveils Next‑Gen Dupixent Amid Rising Competition
There's a fascinating fight brewing between Regeneron and, well, everybody else. But what do we call it? Dupixent, the treatment for atopic dermatitis and other autoimmine issues that $REGN sells with Sanofi, is one of the biggest selling drugs in the...
Moderna Swaps Vaccine Chief as Development Hurdles Rise
Another possible data point on the challenges for new vaccine development: Moderna's chief medical officer, Jacqueline Miller, a longtime vaccine developer who rose through the ranks at GSK and Merck, is departing. David Berman, a veteran of immuno-oncology efforts at AstraZeneca...
Bioinformatics Needs Nuance, Not Hard Cutoffs
You can not do Bioinformatics with hard cutoffs and thresholds Let me tell you something real: Biology is more about p-values. It’s messier than that. 🧵 https://t.co/iewqWMvU6D
Funding Uncertainty Threatens Future US Science Talent
With continued uncertainty over federal government support for biomedical research, PhD students are struggling to find labs willing to take on new students, @JonathanWosen reports. New students are the future of US science. https://t.co/1eeq2PAbCm
LLMs Poised for Near‑term Breakthroughs via Autonomous Labs
Not true. LLMs can run experiments with access to an autonomous lab and this is where they'll make scientific breakthroughs in the near term. Running experiments is about logical experimental planning (controls, replicates, etc), data analysis, and cycling on that. ...
FDA Rejects Anktiva Expansion After Mischaracterized Meeting
My colleague @adamfeuerstein is reporting today that @DrPatrick "mischaracterized the outcome of a face-to-face meeting he had with FDA officials" to broaden the use of Anktiva, the bladder cancer drug that is sold by ImmunityBio, where Soon-Shiong is chairman. Adam reports...
Ex‑Vaccine Court Lawyer Now Guides
This Teen Never Got His Day in Vaccine Court. His Former Lawyer Now Advises RFK on Its Overhaul. This story complicates the simple. https://t.co/RSrad8WOnh
Leaked Data Reveals Mechanisms of JNJ and MRK ADCs
With a tipoff from a friend, and some info that probably shouldn't have been posted in a trial registry, the mechanisms of ADCs JNJ-95437446 $JNJ & SKB571/ MK-2750 $MRK have been revealed. Quite amazing given the recent $GMAB news. Via...
SNY Drops Alphamedix, Opening Window for CATX
Looks like $SNY discontinued Alphamedix/ SAR447873, licensed in Sep 2024 from Radiomedix & Orano Med, h/t B Riley. @ByMadeleineA covered it at #Esmo25 and flagged dysphagia & renal tox. https://t.co/6L2O0c5cOA Good news for $CATX?
Anti‑vax Groups Target State Vaccine Mandates After CDC List
#CDC sets the list of vaccinations recommended for all kids. But decisions about which inoculations kids require for school entry are made at the state level. Anti-vax forces are shifting their focus there @danielpayne.bsky.social & @isabellacueto.bsky.social report. https://t.co/9VPajcWzdI
Vaccines Strain Pediatric Practices, Not Boost Doctor Profits
People who oppose #vaccines often claim that doctors push them because they're paid to by Pharma or that vaccine administration is a big revenue source for doctors. The reality: Delivering vaccine puts an economic strain on many pediatric practices. https://t.co/cyJj1M2SPB
Understanding Login vs Interactive Shells in Bioinformatics
Bioinformatics is more about biology and code. It's shells and sessions, exports and environments. Ever been confused by “login shell” vs “interactive shell”? This thread is for you. 🧵 https://t.co/DfB8BEztiD
Biopharma Sentiment Surges, Fueling M&A and IPO Boom
Biopharma sentiment just snapped higher $XBI BPSI index jumped 78 to 90 in Q1. That is not a grind. That is a turn. Under the hood: >Current Conditions surged 58 to 75. Pain is easing now, not someday. >12-month Expectations hit 100 for the first...
Team Achieves Safe Age‑Reversal Breakthrough at LiFE BIOSCIENCES
Meet the LiFE BIOSCIENCES team, from L to R, Dr. Michael Ringel (COO), Dr. Sharon Rosenzweig-Lipson, (CSO) and Jerry McLaughlin (CEO). Not pictured Amit Shashank (CAO) and my co-founder and founding CEO, Tristan Edwards. A shout out to my lab...
Chris Petty Advances Cell Age Reset, ER‑100 Trials Near
PhD student Chris Petty presents his latest results to the lab. His project is to uncover the mystery of how it’s possible to reset the age of a cell. Where does the back up lie? It’s one of the biggest...
FDA Guidance Clears Path for Wearable Wellness Claims
An inventive new guidance from @US_FDA, opens opportunities for wellness claims for wearable devices like blood pressure. Enables innovation that empowers consumers and providers, and creates avenues for technology-enabled, high-access primary care. https://t.co/sxmD1DNkNW
Shared Decision
Wondering why there's such a fuss about pushing some #vaccine recommendations to "shared clinical decision making"? The term is being conflated with "informed consent," suggesting it's about empowering parents. This isn't that; good take here. https://t.co/F0n0fYFczY https://t.co/h5VO475NmS
Trump Ties Gavi Aid to Phasing Out Thimerosal Vaccines
Reuters reports the Trump adminstration wants to condition any future funding to @gavi on the organization agreeing to phase out use of vaccines containing the preservative thimerosal. I wrote late last year about how unnecessary & impractical that would be....
Model Failures Stem From Data, Not Algorithm Power
1/ You think your ML model fails because it’s “not powerful enough”? No. It’s your data. Garbage in, garbage out. Here’s what most AI scientists miss when using public RNA-seq or single-cell data 👇 https://t.co/dVezFRLHkW
UK Trails Peers in Newborn Disease Screening Policies
Why is the UK so far behind peer countries in terms of the diseases it screens babies for at birth, diseases for which early treatment makes an enormous difference? @statnews 's @DrewQJoseph explores why. https://t.co/stNqZdcV94
Immune Synapse Crosstalk Directs T Cell and Dendritic Cell Functions
How crosstalk at the immune synapse shapes T cell and dendritic cell biology https://t.co/DtqWi1PWhU https://t.co/Yw3sO2UgSX
Inherited Messy Bioinformatics Code? Learn Better Practices
You inherit someone else’s bioinformatics code. No comments. No structure. Variable names like x1, foo, temp2. And now it’s your problem. Let’s talk about that experience—and how to do better. https://t.co/RqCDNPwhMD
CT‑388 Dual GLP‑1/GIP Shows Potent, Durable Weight Loss
Didn’t know $RHHBY was in obesity? They are. Genentech’s CT-388 (dual GLP-1/GIP) showed Ph2 data (n=469) & it might be differentiated (TBD): >48w: −22.5% PBO-adj (efficacy est) / −18.3% treatment-regimen >BMIpreDM to normoglycemia: 73% vs 7.5% >d/c: 5.9% vs 1.3% >No plateau; clear dose-response 💡Mechanistic...